A groundbreaking study from the University of Cambridge has revealed that higher levels of testosterone in the blood are associated with an increased risk of coronary artery disease (CAD), the leading cause of heart attacks worldwide, particularly among men. Conducted by researchers at the MRC Epidemiology Unit, this research challenges long-held assumptions and provides crucial genetic evidence to guide clinical practices and public health policies in the United Kingdom.
Coronary artery disease occurs when the arteries supplying blood to the heart become narrowed or blocked by plaque buildup, a process known as atherosclerosis. This can lead to chest pain, heart attacks, or heart failure. In the UK, cardiovascular diseases remain a major health concern, with approximately 1.9 million people diagnosed with coronary heart disease (CHD) in England alone as of the financial year ending March 2025. The British Heart Foundation reports that CHD claims the lives of one in eight men, underscoring the urgency of understanding modifiable risk factors like hormone levels.
🔬 The Cambridge Study: Methodology and Genetic Insights
The study, titled "Higher circulating testosterone linked to higher CAD risk in men," employed Mendelian randomization (MR), a sophisticated epidemiological technique that uses genetic variants as natural proxies for exposure levels. Mendelian randomization mimics randomized controlled trials by leveraging the random assortment of genes inherited from parents, minimizing confounding factors like lifestyle or reverse causation.
Researchers analyzed data from over 400,000 adults in the UK Biobank—a vast biomedical database—and more than one million individuals from the CARDIoGRAMplusC4D consortium, which focuses on genetic factors in CAD. They identified genetic variants robustly associated with blood testosterone concentrations and examined their links to CAD outcomes.
This approach provided causal evidence: men with genetically predicted higher testosterone levels faced a 17% increased odds of developing CAD. The effect was mediated partly through elevated blood pressure, a well-known CAD risk factor. No significant association was observed in women, highlighting sex-specific hormonal influences on cardiovascular health.
Key Findings in Detail
The lifetime risk of CAD for the average person stands at about 7.3%, but genetically higher testosterone could elevate this to 8.5% in men. This seemingly modest increase translates to substantial population-level impacts, especially as testosterone use rises. The study also explored other outcomes, finding no strong links to thromboembolism, heart failure, or myocardial infarction beyond CAD.
- 17% higher CAD risk in men with genetically elevated testosterone.
- Partial mediation via increased systolic blood pressure.
- No CAD association in women.
- Implications for supraphysiological levels from supplementation.
Background: Testosterone's Dual Role in Men's Health
Testosterone, the primary male sex hormone produced mainly in the testes, regulates muscle mass, bone density, red blood cell production, and sexual function. Levels peak in early adulthood and decline gradually with age, affecting up to 8% of men over 50—a condition called hypogonadism.
Observational studies have paradoxically linked low testosterone to higher CAD risk, fueling interest in testosterone replacement therapy (TRT). However, randomized trials like the TRAVERSE study (published in the New England Journal of Medicine) found no overall increase in major adverse cardiovascular events (MACE) with TRT in high-risk men, though subgroups showed nuances. The Cambridge findings resolve some discrepancies by suggesting that while low testosterone correlates with poor health (due to confounders like obesity), elevating it above natural levels may confer risks.
In the UK, TRT prescriptions have surged, partly driven by social media influencers promoting it for muscle gain and vitality in young men without medical need. The NHS approves TRT for confirmed hypogonadism but lacks specific cardiovascular warnings, unlike the US FDA.
Contrasting Previous Research and Expert Perspectives
Prior research paints a mixed picture. A 2023 NEJM trial involving over 5,000 men showed TRT did not increase heart attacks or strokes compared to placebo. Yet, some retrospective analyses reported up to 55% higher MACE risk with long-term exposure. UK guidelines from bodies like the Royal United Hospitals Bath note uncertain cardiovascular effects but affirm safety in monitored settings.
Emily Morbey, lead author and PhD student at Cambridge's MRC Epidemiology Unit, stated: “Our work indicates that high levels of testosterone in the blood increase the risk of coronary artery disease... When there is a medical need to boost testosterone, the benefits are likely to outweigh the risks, but this might not necessarily be the case when taken to boost performance.”
Professor Ken Ong added: “Our results suggest there’s a need for more consistent warnings” in the UK.University of Cambridge press release
UK Context: Heart Disease Burden and Policy Gaps
In England, CVD affects over 6.4 million people, with men disproportionately impacted. The government’s December 2025 CVD profiles highlight persistent inequalities, despite prevention efforts reducing diagnoses by 20% over two decades. CHD mortality remains high, killing more women than breast cancer but hitting men earlier.
The NHS monitors TRT patients for prostate issues and hematocrit but cardiovascular screening varies. This Cambridge study, funded by the Medical Research Council and NIHR Cambridge Biomedical Research Centre, calls for updated guidance to balance TRT benefits—like improved sexual function and muscle strength—against CAD risks.
For those in higher education research jobs, this underscores opportunities in genetic epidemiology and endocrinology at institutions like Cambridge.
Implications for Testosterone Replacement Therapy
TRT involves gels, injections, or patches to restore physiological levels (typically 300-1000 ng/dL). Benefits include reduced fatigue and better metabolic health in hypogonadal men. However, pushing levels higher risks erythrocytosis (thickened blood), sleep apnea, and now genetically evidenced CAD.
- Monitor blood pressure and lipids pre- and post-TRT.
- Avoid in men with existing CAD without specialist oversight.
- Counsel against non-medical use for bodybuilding or anti-aging.
Step-by-step risk assessment: 1) Confirm low T via two morning blood tests; 2) Rule out confounders like obesity; 3) Baseline ECG if high-risk; 4) Regular follow-ups every 3-6 months.
Broader Impacts on Public Health and Research
This study spotlights the MRC Epidemiology Unit's prowess in leveraging big data for causal inference, attracting top talent in research assistant jobs and postdoctoral positions. Future work may explore gene-hormone interactions or sex differences in steroid metabolism.
Stakeholder views: Endocrinologists advocate personalized dosing; cardiologists urge caution in athletes. Real-world case: A 2025 UK audit found 15% of TRT users under 40 lacked hypogonadism diagnosis, amplifying misuse concerns.
Actionable Insights and Future Outlook
Men concerned about testosterone: Prioritize lifestyle—exercise, diet, sleep—to naturally optimize levels. Consult GPs for symptoms like fatigue or low libido, not influencers. Researchers eyeing academic careers can draw inspiration from Cambridge's model.
Looking ahead, longitudinal trials integrating MR could refine TRT protocols. UK policy may evolve, mirroring FDA black-box warnings. This research exemplifies how university-led innovation drives health advancements.
For career advice in higher ed, explore higher ed jobs or rate my professor for insights into leading academics.
Photo by Irina Nikiforova on Unsplash
Conclusion: Balancing Hormones and Heart Health
The Cambridge study reframes testosterone not just as a vitality booster but a potential cardiovascular double-edged sword. By providing robust genetic evidence, it empowers informed decisions, from clinical prescribing to personal wellness. As UK universities like Cambridge pioneer such discoveries, they solidify their role in tackling national health challenges. Stay informed, consult professionals, and consider opportunities in university jobs advancing this field.